Biotechnology

It could become the first publicly listed company focused on AI-driven nanodelivery.

The company is preparing multicenter trials as brain-computer interface technology moves closer to clinical deployment.

A new class of PA-targeted drugs promises faster relief, but high prices and uneven access could slow uptake.

Managing partner Shan Fu says the firm can generate stronger returns through its asset-centric accelerator model.

The firm’s share price has nearly tripled over the past year, driven by steady cash flow, global expansion, and a distinct strategy.

Despite its record scale, the deal’s co-co model highlights both rising ambition and lingering skepticism in a cooling market.

Investors are reassessing de novo drug design as firms close major BD transactions.

Chair Zhao Yan is steering the company away from hype-driven marketing, investing in synthetic biology to rebuild growth and credibility.